Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00559273 · OUTCOME

Percentage of Participants With Red Blood Cell (RBC) Transfusions

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis · Source last updated 2016-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Baseline up to Week 28

What was measured

The percentage of participants who received RBC transfusions during the titration and evaluation periods were reported.

Analysis population: ITT population.

Groups in this outcome

Mircera

Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.

Darbepoetin Alfa

Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Mircera153
Darbepoetin Alfa154

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Mircera3.3Not reportedNot reportedNot reportedNot reported
Darbepoetin Alfa6.5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3.3
      2. group Id
        OG001
        value
        6.5
denoms
  1. counts
    1. group Id
      OG000
      value
      153
    2. group Id
      OG001
      value
      154
    units
    Participants
description
The percentage of participants who received RBC transfusions during the titration and evaluation periods were reported.
groups
  1. description
    Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
    id
    OG000
    title
    Mircera
  2. description
    Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
    id
    OG001
    title
    Darbepoetin Alfa
param Type
NUMBER
population Description
ITT population.
reporting Status
POSTED
time Frame
Baseline up to Week 28
title
Percentage of Participants With Red Blood Cell (RBC) Transfusions
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice